iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference
March 11 2022 - 8:00AM
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of
next-generation biopharmaceuticals and pioneer of the sustainable,
plant-based
FastPharming Manufacturing System®,
today announced that its Chairman & CEO, Tom Isett, will
present virtually at the Oppenheimer 32nd Annual Healthcare
Conference on Thursday, March 17, 2022 at 2:40 p.m. Eastern Time.
The presentation will be broadcast live and
archived on the Company's website at www.ibioinc.com under "News
& Events" in the Investors section.
About iBio, Inc.
iBio is a developer of next-generation
biopharmaceuticals and a pioneer in sustainable, plant-based
biologics manufacturing.
Its FastPharming System® combines vertical
farming, automated hydroponics, and novel glycosylation
technologies to rapidly deliver high-quality monoclonal antibodies,
antigens, and other proteins. iBio is developing proprietary
biopharmaceuticals for the treatment of cancers, as well as
fibrotic and infectious diseases. The Company’s wholly-owned
subsidiary, iBio CDMO LLC, provides FastPharming
Contract Development and Manufacturing Services along with
Glycaneering Development Services™ for advanced
recombinant protein design. For more information, visit
www.ibioinc.com.
Contact:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024